期刊文献+

质子泵抑制剂预防非甾体类抗炎药相关性溃疡复发的荟萃分析 被引量:5

Meta-analysis of proton pump inhibitor for preventing recurrence of non-steroidal anti-inflammatory drugs-induced ulcers
原文传递
导出
摘要 目的评价质子泵抑制剂(PPI)预防非甾体类抗炎药(NSAID)相关性溃疡复发的临床疗效和安全性。方法检索中国生物医学文献数据库、Medline等,纳入PPI预防NSAID相关性溃疡复发的所有临床随机对照试验。采用Cochrane协作网提供的RevMan4.2软件进行荟萃分析。结果10项随机临床试验共3361例患者纳入研究。荟萃分析结果显示,PPI显著降低NSAID相关性溃疡的复发率(8.7%),与对照组比较差异有统计学意义(17.2%,P=0.03)。其中,接受埃索美拉唑治疗和兰索拉唑治疗的患者溃疡复发率明显减低(4.4%和18.0%),与对照组比较差异均有统计学意义(14.7%和28.7%,P值分别为0.01和0.05),而奥美拉唑组与对照组相比并无明显优势(P=0.16)。不同剂量PPI比较,埃索美拉唑20mg/d、40mg/d和兰索拉唑15mg/d组NSAID溃疡的复发率分别为4.4%、4.3%和19.7%。将NSAID分层分析发现,PPI可有效预防非选择性NsAID溃疡的复发(P=0.009),但对选择性环氧合酶2抑制剂无明显优势(P=0.58)。未发现PPI治疗组和对照组发生明显的药物不良反应。结论以埃索美拉唑为主的PPI在不停用NSAID的情况下,能有效预防已经发生的NSAID相关性溃疡的复发,疗效可靠、耐受性好。 Objective To assess tbe clinical efficacy and safety of proton pump inhibitors (PPI) for preventing recurrence of non-steroidal anti-inflammatory drugs (NSAIDs)-induced upper gastrointestinal ulcers using meta-analysis. Methods Mono- or multicenter randomized controlled clinical trials related to NSAIDs-induced ulcers were retrieved from database of China Biological Medicine and Medline from 1966 to 2007. The data were analyzed by RevMan 4. 2 software using random or fixed effects model. Results Ten randomized controlled trials including 3361 patients were included. The meta-analysis revealed that PPI treatment significantly reduced the recurrent rate of NSAIDs-associated ulcers (8.7%) in comparison with controls (17.2%, P=0. 03). Those who received esorneprazole (4. 4%) or lansoprazole (18. 0%) had a low recurrence of peptic ulcers compared with controls (14.7% or 28.7%, P value 0.01 or 0. 05). But there was no significant differencebetween omeprazole and controls (P=0. 16). The recurrence of NSAIDs associated ulcers in patients treated with esomeprazole 20 mg or 40 mg and lansoprazole 15 mg were 4.4%, 4.3% and 19.7% respectively. The stratify analysis showed that PPI therapy could effectively reduce recurrentce of non-selective NSAIDs-induced ulcer (P= 0. 009), but failed to selective cyclooxygenase (COX)-2 inhibitor induced ulcer. No severe adverse reactions were found in PPI groups. Conclusion PPI is effective and safe in prevention of NSAIDs-related ulcers without discontinuation of NSAIDs.
出处 《中华消化杂志》 CAS CSCD 北大核心 2009年第7期471-475,共5页 Chinese Journal of Digestion
关键词 质子泵抑制剂 非甾体类抗炎药 随机临床试验 荟萃分析 Proton pump inhibitors Anti-inflammatory agents, non-steroidal Randomized controlled trials as topic Meta-analysis
  • 相关文献

参考文献18

  • 1Morgner A,Miehlke S,Labenz J.Esomeprazole:prevention and treatment of NSAID-indueed symptoms and ulcers.xpert Opin Pharmacother,2007,8:975-988.
  • 2Thomas J,Straus WL,Bloom BS.Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms.Am J Gastroenteroh 2002,97:2215-2219.
  • 3Rostom A,Dube C,Wells G,et al.Prevention of NSAID-induced gastroduodenal ulcers.Cochrane Database Syst Rev,2002,4:CD002296.
  • 4Chan FK,Ching JY,Hung LC,et al.Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.N Engl J Med,2005,352:238-244.
  • 5Lai KC,Chu KM,Hui WM,et al.Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications.Clin Gastroenterol Hepatol,2006,4:860-865.
  • 6Scheiman JM,Yeomans ND,Talley NJ,et al.Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.Am J Gastroenterol,2006,101:701-710.
  • 7Chan FK,Wong VW,Suen BY,et al.Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk:a double-blind,randomised trial.Lancet,2007,369:1621-1626.
  • 8Graham DY,Agrawal NM,Campbell DR,et al.NSAIDAssociated Gastric Ulcer Prcvention Study Group.Ulcer prevention in long-term users of nonsteroidal antiinflammatory drugs:results of a double-blind,randomized,multicenter,active-and placebo-controlled study of misoprostol vs lansoprazole.Arch Intern Med,2002,162:169-175.
  • 9Lai KC,Lain SK,Chu KM,et al.Lansoprazole for the prevention of recurrences of ulcer complications from longterm low-dose aspirin use.N Engl J Med,2002,346:2033-2038.
  • 10Goldstein JL,Huang B,Amer F,et al.Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low dose aspirin:results of a post HOC subanalysis.Clin Ther,2004,26:1637-1643.

二级参考文献7

  • 1Silverstein FE,Faich G,Goldstein JL,et al.Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis:the CLASS study:a randomized controlled trial[J].JAMA,2000,284 (10):1247-1255.
  • 2Bombardier C,Laine L,Reicin A,et al.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis[J].N Engl J Med,2000,343 (21):1520 -1528.
  • 3Huang JQ,Sridhar S,Hunt RH.Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease:a meta-analysis[J].Lancet,2002,359 (9300):14-22.
  • 4Silverstein FE,Graham DY,Senior JR,et al.Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs[J].Ann Intern Med,1995,123:241-249.
  • 5Hawkey CJ,Karrasch JA,Szczepanski L,et al.Omeprazol compared with misoprostol for ulcers associated with nonsteroidal antinflammatory drugs[J].New Engl J Med,1998,338 (11):727-734.
  • 6Yeomans ND,Tulassay Z,Juhasz L,et al.A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs.Acid Suppression Trial:ranitidine versus omeprazole for NSAID-associated ulcer[J].N Engl J Med,1998,338(11):719 -726.
  • 7陈文,胡善联,王吉耀,刘厚钰,刘天舒,李兆申,江石湖,袁耀宗,王根生.非甾体抗炎药致上消化道出血的经济负担研究[J].中华风湿病学杂志,2002,6(1):31-34. 被引量:12

共引文献12

同被引文献41

  • 1张晓军,黎红光,栾双梅,许爱翠.消化性溃疡并出血患者早期再出血的危险因素预测[J].中华消化杂志,2006,26(2):135-136. 被引量:19
  • 2陈清,卢秀华,薛占英,史玮,闫雪立.pH值及温度对注射用奥美拉唑钠溶液质量的影响[J].中国药业,2007,16(9):23-24. 被引量:24
  • 3Morgner A, Miehlke S, Labenz J. Esome?prazole , prevention and treatment of NSAID - induced symptoms and ulcers [J]. Expert Opin Pharmacother, 2007, 8 (7): 975 - 988.
  • 4Matsui H, Shimokawa 0, Kaneko T, et aI. The pathophysiology of non - steroidal anti - inflammatory drug (NSAID) - induced mu?cosal injuries in stomach and small intestine [J]. J Clin Biochem Nutr, 2011, 48 (2): 107 -111.
  • 5Tiihonen K, Tynkkynen S, Ouwehand A, et aI. The effect of ageing with and. without non - steroidal anti - inflammatory drugs on gastrointestinal microbiology and immunology [J]. Br J Nutr, 2008, 100 (1): 130- 137.
  • 6Targownik LE, Metge CJ, Leung S. Underu?tilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications [J]. Aliment Pharmacol Ther, 2008, 28 (1): 88 -96.
  • 7Koch TR, Petro A, Darrabie M, et aI. Effects of esomeprazole magnesium on nonste?roidal anti - inflammatory drug gastropathy [J]. Dig Dis Sci, 2005, 50 (1): 86- 93.
  • 8Miwa H, Osada T, Nagahara A, et aI. Effect of a gastro - protective agent, rebamip?ide, on symptom improvement in patients with functional dyspepsia: a double - blind placebo - controlled study in Japan [J]. J Gastroenterol Hepatol, 2006, 21 (12): 1826 -1831.
  • 9王小蕾,王蔚虹.长期服用质子泵抑制剂需要关注的临床问题[J].临床药物治疗杂志,2009,7(4):6-11. 被引量:26
  • 10张勇,余长永,邹建军,燕翔,贺春晖,马海涛,倪斌,陈绍良.质子泵抑制剂对氯吡格雷作用机制及临床研究进展[J].世界华人消化杂志,2010,18(1):75-80. 被引量:18

引证文献5

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部